China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced receiving the green light from the regulatory body in Singapore to initiate a Phase I clinical study for its radiotherapeutic drug, 177Lu-LNC1004, which targets fibroblast activation protein (FAP) and is under development to treat FAP-positive advanced solid tumors. This marks a significant step forward in the global development of this innovative treatment, as there is no similar product approved anywhere in the world.
177Lu-LNC1004: A Pioneering Treatment for FAP-Positive Tumors
177Lu-LNC1004 is designed to specifically bind to FAP on the surface of cancer-associated fibroblasts (CAF) membranes, thereby achieving precise tumor treatment by delivering 177Lu radionuclide to solid tumors that test positive for FAP. FAP is highly expressed in many epithelial tumor-associated fibroblasts, including gastric, esophageal, lung, colorectal, and ovarian cancers, with minimal or no expression in normal or benign tissues.
Preclinical and Clinical Evidence of Efficacy
Preclinical and clinical studies have demonstrated that 177Lu-LNC1004 can effectively and precisely target solid tumor cells such as gastric, esophageal, lung, and thyroid cancers, showing a significant therapeutic effect. The product’s chemical structure is modified with Evans blue (EB) Fluorescence, which enhances the pharmacokinetic and pharmacological properties of the probe. This modification increases the effective absorption of drugs by tumors, extends the treatment time window, and allows for a reduction in the dosage of radioactive nuclides while maintaining or improving treatment effects, thereby reducing the treatment cost for patients.-Fineline Info & Tech
